(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 10.91% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Neogenomics's revenue in 2025 is $672,361,000.On average, 6 Wall Street analysts forecast NEO's revenue for 2025 to be $95,860,417,061, with the lowest NEO revenue forecast at $94,150,324,505, and the highest NEO revenue forecast at $96,726,788,455. On average, 7 Wall Street analysts forecast NEO's revenue for 2026 to be $106,431,383,537, with the lowest NEO revenue forecast at $104,802,368,518, and the highest NEO revenue forecast at $107,318,346,052.
In 2027, NEO is forecast to generate $117,008,012,572 in revenue, with the lowest revenue forecast at $114,191,919,457 and the highest revenue forecast at $119,467,107,135.